Studies regularly face big obstacles and steep hurdles – and this pivotal Phase III study was no different. Recruitment challenges and a lack of regulatory guidance created pressure right from the start.
But add in a hurricane – and an earthquake destroying one of our sites? Suddenly, the odds seemed insurmountable. Find out how we navigated through these setbacks – and what the final outcome was for our client:
Achieving Market Approval in a Phase III Breakthrough Therapy for Lupus Nephritis
Read more